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Abstract 
Sublingual film dosage forms for drugs used for fast symptomatic treatment have promise 
because they allow a rapid onset of action. The aim of this study was to prepare films of 
silodosin intended for sublingual administration for the symptomatic treatment of benign 
prostatic hyperplasia in men. Hydroxypropyl methylcellulose (HPMC) or hydroxypropyl 
methylcellulose acetate succinate (HPMC-AS) were used as film-forming polymers. The 
effects of the polymers and the surfactant tocopherol polyethylene glycol succinate (TPGS) 
on the physico-mechanical properties and dissolution behavior of the films in simulated saliva 
were investigated. The eight silodosin oral films developed (F1–F8) contained 8 mg silodosin 
per 6 cm2 film and HPMC or HPMC-AS in drug:polymer ratios of 1:5 or 1:3, while four also 
contained TPGS (0.5 % w/w). The films were characterized using DSC, TGA, SEM, and 
PXRD and the mechanical properties were investigated by measuring tensile strength, 
elongation at break and Young’s modulus. The mechanical properties of the films were 
dependent on the ratio of polymer used. The in vitro dissolution and drug release studies 
indicated that HPMC-AS films disintegrated more quickly than HPMC films. Silodosin was 
shown to be dispersed within the polymers. Despite silodosin being submicronized in the 
HPMC films, the dissolution and drug release rate (time for 80% release) from HPMC films 
was significantly faster than from HPMC-AS films. TPGS increased the drug release rate to a 
greater extent with HPMC than with HPMC-AS. The degree of saturation of formulation F4 
was >1, which shows potential for improving oral absorption of silodosin. 
Keywords: 
Silodosin, sublingual oral films, HPMC, HPMC-AS, TPGS, simulated saliva 
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1. Introduction 
Conventional oral dosage forms, such as tablets or capsules, have challenges related to 
dissolution, absorption and poor bioavailability for some drugs and can also be associated 
with problems related to patient compliance [1, 2, 3]. Alternative drug delivery systems such 
as oromucosal formulations can be used to overcome these drawbacks [4]. Oromucosal 
formulations such as oral films have recently been receiving attention from the 
pharmaceutical industry because of their unique advantages [5, 6]. For instance, oral films are 
easy to administer, do not require chewing or intake of water, and disintegrate and dissolve 
rapidly to release the drug when placed in the oral cavity [7, 8]. This has the potential to 
improve patient compliance, mainly for pediatric and geriatric patients but also for others with 
mental disorders, dysphagia or emesis [9, 5]. Drugs formulated as oral films intended for 
sublingual administration will be directly and rapidly absorbed into the systemic circulation 
without passing through the gastrointestinal tract (GIT), thereby bypassing first-pass 
metabolism in the liver [10, 11]. The relatively extensive vascularity and high permeability of 
the sublingual mucosa and membranes can facilitate rapid absorption of the formulated drug 
and instant bioavailability [12, 13, 14, 5].  
Oral films can be prepared by various methods, including solvent casting, hot-melt extrusion, 
electrospinning, freeze drying and ink-jet printing [15, 16, 17, 18]. The solvent-casting 
method is appropriate and feasible for manufacturing on an industrial scale. Usually, oral 
films contain polymers, plasticizers, drug, surfactants and taste-masking agents (sweeteners 
and flavors) as required. The film-forming ability and water solubility are the main 
considerations for selecting the polymer. The polymer to plasticizer ratio is also crucial, as 
this affects the physico-mechanical stability of the final product, and consideration of this 
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attribute is thus required in the design and development process for oral film formulations. 
Garsuch and Breitkreutz have reported that the cellulose-derived polymer hydroxypropyl 
methylcellulose (HPMC) forms films well and has better mechanical properties than other 
tested excipients [19]. In another study, Visser et al. reported the optimal physico-mechanical 
properties of films prepared with combined HPMC and polyol plasticizers [20]. Oral films 
can be considered as solid dispersions and the systematic determination of the drug’s 
solubility in the film-forming excipients (polymers/surfactants) using the appropriate 
techniques is an important development step.  
Cellulose-based polymers such as HPMC and hydroxypropyl methylcellulose acetate 
succinate (HPMC-AS) help to stabilize the physical structure of the drug, preventing it from 
recrystallizing, and increasing its supersaturation during dissolution [21]. It could thus be 
interesting to evaluate the potential of these polymers in the preparation of oral films intended 
for sublingual drug absorption. The oral cavity has a smaller surface area and less dissolution 
medium (i.e. saliva) than the GIT and the polymers could provide a vital boost to the 
dissolution and subsequent absorption of drugs administered as a film [22]. Furthermore, the 
film-forming properties and potential of HPMC and HPMC-AS in film drug delivery have 
been extensively investigated.  
Surfactants are also an important excipient in the preparation of drug-carrying films, 
particularly for poorly water-soluble drugs. It is well known that surfactants can facilitate 
wettability and enhance the dissolution rate of poorly water-soluble drugs. For example, 
Vuddanda et al. have reported that the addition of surfactant enhanced the dissolution of 
tadalafil nanocrystal-loaded oral films [23]. 
Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland caused by the 
proliferation of prostatic stromal cells. It’s an important cause of lower urinary tract 
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symptoms in men such as frequency, urgency, nocturia, and hesitancy.  BPH is a common 
problem among men after the age of 40 years [24, 25]. Silodosin is a selective α1A 
adrenoceptor blocker that is a safe, effective treatment for the relief of both voiding and 
storage symptoms in patients with BPH [26]. Silodosin is a white to pale yellowish-white 
powder. The partition coefficient [LogP (octanol/water)] of silodosin is 2.87, with 
dissociation constants pKa1 of 8.53 and pKa2 of 4.03. According to the US Food and Drug 
Administration (FDA) label, silodosin is very slightly soluble in water. The oral 
bioavailability of silodosin administered as an oral capsule is nearly 32% and the onset of 
action (maximum urine flow rate) after the first dose occurs in 2-6 hours [27]. Silodosin 
undergoes extensive metabolism involving glucuronidation in the liver [27, 28]. 
Because of these issues, an oral film formulation, intended for sublingual administration, 
could be promising for silodosin. This would facilitate rapid absorption, provide a faster onset 
of action, and have potential for faster relief of symptoms than an oral capsule. In addition, 
patient compliance could be improved, as some patients find films easier to take than 
capsules. Also, the sublingual film formulation of silodosin avoids first-pass metabolism in 
the liver and thus has potential to improve systemic bioavailability. Films can also provide a 
supersaturated concentration of the drug in the saliva, which can improve the oral mucosal 
absorption of poorly soluble drugs. To our knowledge this is the first study of the preparation 
of a sublingual film dosage form for silodosin. 
The main aim of this study was to prepare oral film formulations of silodosin intended for 
sublingual administration. The effects of added polymer and surfactant on the physico-
mechanical and dissolution properties of the films were investigated. The dissolution and 
supersaturation properties of the films were investigated in small volumes of simulated saliva 
to realistically mimic the oral cavity. HPMC and HPMC-AS were investigated as film-
forming polymer excipients in drug:polymer ratios of 1:3 w/w and 1:5 w/w and tocopherol 
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polyethylene glycol 1000 succinate (vitamin E; TPGS) was included as a surfactant. The 
silodosin dose in each film was 8 mg (the daily recommended dose of silodosin according to 
the FDA) and the films were 6 cm2 (2 cm × 3 cm) in area. 
2. Materials and methods 
2.1. Materials 
Silodosin was obtained from Ultra Medica (Damascus, Syria). Hydroxypropyl 
methylcellulose 6cp (Pharmacoat 606) and Hydroxypropyl methylcellulose acetate succinate 
3cp (Hypromellose Acetate Succinate NF) grade AS-HF were obtained from Shin-Etsu 
(Tokyo, Japan). D-α-tocopherol polyethylene glycol 1000 succinate (vitamin E; TPGS) NF 
grade was received as a gift sample from BASF Chemicals (Ludwigshafen, Germany). 
Glycerol and acesulfame potassium were purchased from VWR chemicals (Stockholm, 
Sweden). The water used in all experiments was ultrapure, freshly collected from a Millipore 
water system (Milli Q, Sweden). The other materials were purchased locally and used as 
purchased.  
2.2. Methods 
2.2.1. Drug-polymer miscibility 
Silodosin and the polymers (HPMC or HPMC-AS) were mixed in three ratios (1:1, 1:3 and 
1:5 w/w) to a total weight of 400 mg. The solid dispersions were prepared by the film-casting 
method. The drug and polymers were dissolved in ethanol:water (1:1 v/v) to a volume of 5 
mL. This solution was cast onto a fluoropolymer-coated polyester sheet (Scotchpak® release 
liner 1022, 3 MInc., USA) and dried at 70˚C in an oven for 1 hour. The dried samples were 
then analyzed using differential scanning calorimetry (DSC; TA Instruments Q 1000, USA) to 
investigate the miscibility of the drug and the polymer. 
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2.2.2. Preparation of the casting gel  
The casting gel consisted of HPMC or HPMC-AS (65%), glycerol and propylene glycol (7%), 
and sweetener (2%), with ethanol and water as vehicle, relative to the total weight of the solid 
base. All weights are w/w ratios. Silodosin was dissolved in ethanol (12-13%) and the 
remaining excipients were dissolved in water (87-88%). HPMC or HPMC-AS was gradually 
added to this solution under constant magnetic stirring (800 rpm) at ambient temperature (21 
± 1 ˚C) until a homogeneous gel was obtained. This casting gel was kept for 6-12 h to remove 
the air bubbles. Table 1 shows the overall composition of the prepared films. 
2.2.3. Preparation of drug-loaded films 
The casting gel (10g) was cast onto a fluoropolymer-coated polyester sheet (Scotchpak® 
release liner 1022, 3 MInc., USA) using an automated film applicator equipped with a coating 
knife (Coatmaster 510, Erichsen, Sweden). The silodosin dose of 8 mg was loaded into each 6 
cm2 film by fixing the wet film thickness at 750µm with a casting speed of 5 mm/s, estimated 
from the formula developed by Preis et al, [29]. The cast films were dried in a convective hot-
air oven (Binder, Sweden) at 60 °C for 45-50 min. After drying, the films were carefully 
peeled off, sealed in plastic (polythene) zip pouches, and stored in a desiccator (23 °C/40% 
RH) until further characterization. 
2.2.4. Dry film thickness 
The thickness of the films was measured using a Vernier caliper (Cokraft®, Digital caliper, 
Sweden). The thickness of each film was measured at the four sides and at the middle point. 
The average and standard deviation were calculated. 
2.2.5. Differential scanning calorimetry (DSC) 
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Thermograms of the drug, the drug/polymer blends and the film samples were recorded using 
a differential scanning calorimeter (TA Instruments Q 1000, USA) equipped with a 
refrigerated cooling system. Each sample (1–3 mg) was placed in a standard aluminum pan 
and sealed. The samples were heated at a rate of 10 °C/min from 25 to 120 °C under nitrogen 
purge (50 mL/min). The calorimeter was previously calibrated for temperature and heat 
capacities using indium and sapphire. The results were analyzed using Universal analysis 
software (TA instruments, USA). 
2.2.6. Thermo-gravimetric analysis (TGA) 
A TGA instrument (TA instruments, USA) was used for thermo-gravimetric analysis. 
Approximately 5–8 mg of film (small pieces) were placed in a platinum pan and heated from 
25 to 150 °C at a constant heating rate (10 °C/min) under nitrogen flow (50 mL/min). The 
results were analyzed using Universal analysis software (TA instruments, USA). 
2.2.7. Powder X-ray diffraction (PXRD) 
PXRD patterns from pure crystalline silodosin and the film samples were collected using an 
Empyrean PXRD instrument (PANalytical, Almelo, The Netherlands) equipped with a 
PIXel3D detector and monochromatic Cu Kα X-Ray radiation (λ = 1.54056 Å). The voltage 
and current were 45 kV and 40 mA. The samples (3 × 3 cm2 films) were placed on a silicone 
(zero background) plate which was fitted into the metal sample holder. The samples were 
scanned (diffraction angle 2θ) between 5° and 40°, increasing at a step size of 0.02. All 
patterns were obtained at 25 ± 1 °C. The data were processed using High Score Plus software 
(PANalytical, The Netherlands). 
2.2.8. Mechanical properties 
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The dynamic mechanical strength was tested using a hybrid rheometer in DMA mode (DHR2, 
TA Instruments, Sweden). Briefly, samples of cast films were cut into rectangular strips of 
1×5 cm2 and 1 cm at each end was held between clamps; thus, the effective testing area was 
1×3 cm2. The upper clamp was then used to stretch the film upwards at a constant linear rate 
of 0.1 mm/min until the film ruptured. Stress and strain were computed by Trios® software. 
The tensile strength (TS) and the elongation at break (EB) were obtained from the peak stress 
and the maximum strain, respectively, in the stress vs strain plot. Tensile tests are commonly 
used to determine the robustness of film preparations. The TS is the maximum force applied 
to the film sample at the breaking point and the EB is the length of the film during the pulling 
process. In addition, Young´s modulus or the elastic modulus (EM) describes the influence of 
the strain and its force at this strain on the film area. The EM was obtained from the initial 
elastic deformation region in the stress vs strain plot [30]. 
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2.2.9. Scanning electron microscopy (SEM) 
A Merlin scanning electron microscope (Zeiss, Oberkochen, Germany) equipped with X-Max 
50 mm2 X-ray detectors (Oxford Instruments, Abingdon, UK) was used to examine the 
morphology of the films. The instrument voltage was 20 kV and the current were 1 nA. The 
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selected film samples were coated with tungsten before the examination to increase the 
conductivity of the electron beam. 
2.2.10. HPLC analytical method 
The drug content of the films was analyzed in a high-performance liquid chromatography 
(HPLC) system (Agilent systems Inc., USA) with an auto sampler. The sample separation was 
performed on an Agilent Eclipse-plus C18 column (5 µm, 250 mm × 4.6 mm) with a mobile 
phase of 25 mM potassium-dihydrogen phosphate buffer (pH 7.0) and acetonitrile 40:60 (v/v) 
at 25˚C. The flow rate was 1 mL/min. The determination wavelength was 269 nm [31]. 
2.2.11. Drug content 
The films (1 × 1 cm2) were placed in a volumetric flask containing 10 mL of water and 
ethanol (1:1 v/v) and kept under magnetic stirring at 100 rpm for 1 h. The obtained solution 
was filtered through a syringe filter (0.2 µm) and the filtrate was analyzed for drug content 
using HPLC. 
2.2.12. Disintegration time 
Samples (1 × 1 cm2) were placed in a Petri dish containing 2 mL of water and shaken at 
60 rpm using an orbital shaker water bath at 37 ± 1 °C. The disintegration time of the films 
was evaluated using a modified Petri dish method [19]. The time to disintegration or 
disruption was measured with a stopwatch. 
2.2.13. Solubility studies 
The solubility of silodosin was determined in simulated saliva containing pre-dissolved 
HPMC or HPMC-AS with or without TPGS in concentrations similar to those used in the film 
formulations. The simulated saliva was prepared using compositions mentioned by Hobbs and 
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David [32]. An excess of drug was added to conical flasks containing 10 mL of saliva and the 
other polymer-surfactant excipients. The flasks were tightly closed and placed in a shaker 
water bath at 37°C. After 48 h, the separated aliquots were filtered through a 0.45 µm filter, 
diluted appropriately and analyzed using HPLC. Each experiment was performed in triplicate 
(n = 3) and the results were reported as means ± standard deviation (SD). 
 
 
2.2.14. In vitro dissolution in simulated saliva 
Non-sink dissolution studies were carried out in simulated saliva at pH 6.8. The films (F1-F8; 
2 × 3 cm) were carefully dropped into 10 mL dissolution medium under continuous orbital 
shaking (60 rpm) at 37˚C. Experimental conditions such as volume of the dissolution medium, 
shaking speed and temperature were chosen according to literatures [33, 34, 35, 36, 37]. 
Samples of the medium were then withdrawn at different times, filtered through syringe filters 
(0.45 µm) and analyzed by HPLC.  
The degree of supersaturation (DS) was calculated from the drug concentrations at different 
times during dissolution of the films (F1-F8) and the drug concentrations at equilibrium. DS 
calculations for the formulated drug were based on equation 3:  
DSt =

0
								                                                                                                                          (3) 
Where: Ct is the drug concentration at time t and Ceq is the equilibrium solubility of the drug 
in the test medium. The obtained values of DS for F1-F8 were plotted versus time.  
2.2.15. Statistical analysis 
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One-way ANOVA and Tukey's post hoc multiple comparisons were used to determine 
statistically significant differences (p < 0.05). All results were expressed as averages plus 
standard deviation (n=3).  Mechanical properties were investigated using n = 5. 
3. Results and Discussion 
3.1. Thermal and solid-state properties 
DSC thermograms of pure and amorphous silodosin showed a sharp endothermic event at 
~106 ˚C for pure silodosin, confirming its crystalline state. This is in line with results from a 
previous report by Singh and Mirmehrabi [38]. The endothermic peak was absent in case of 
amorphous silodosin confirming an amorphous state. To choose the best drug: polymer ratio 
in the miscible system for forming films, different polymer ratios were investigated (Fig. 1). 
The melting peak of the crystalline silodosin (~106 ˚C) was absent in the thermograms of all 
the silodosin: polymer systems under investigation, indicating that all the systems were 
miscible and formed solid dispersions (Fig. 1). These results confirmed the formation of 
miscible dispersions with the studied ratios. Thus, the silodosin: polymer ratios 1:3 and 1:5 
were chosen for film formulations with either HPMC or HPMC-AS, with or without the 
surfactant (TPGS) (Table 1). The polymer content was necessary for casting the films and 
preventing drug recrystallization during storage. 
The thermal properties of pure silodosin and the formulated films were assessed as shown in 
Fig. 2. The melting peak of the crystalline form was absent from the DSC thermograms of all 
the prepared films (F1-F8), which was interpreted as molecular dispersion of the drug in the 
polymer (Fig. 2). ElMeshad and El Hagrasy have also reported the formation of a uniform 
dispersion with complete molecular miscibility of different film components in films prepared 
with HPMC [39]. A similar finding of solid dispersions of amorphous nifedipine in HPMC-
AS was reported by Curatolo et al. [21]. A glass transition temperature (Tg) of 92.9 ˚C for 
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HPMC-based films and 79.28 ˚C for HPMC-AS-based films was observed (data not shown). 
The Tg values for the films were higher than the temperature in the buccal cavity and also the 
environmental temperature, which is important for keeping the product stable during storage 
(from the perspective of the product logistics from manufacturing to consumption) [40, 19].  
TGA was performed to determine the moisture content in the prepared films, as shown in Fig. 
3. Weight loss was between 0.9 and 1.6 % for the films prepared with the HPMC polymer 
(F1-F4) and between 1.6 and 1.9 % for the films prepared with the HPMC-AS polymer. These 
results suggest that the film formulations retained some moisture, possibly because of the 
inherent water sorption properties of both polymers, as suggested by the moisture content in 
pure HPMC and HPMC-AS (data not shown). A moisture content of about 2% is essential for 
flexibility of the films and this was found not to affect the physical stability of the solid 
dispersions, as confirmed by DSC and PXRD analysis (Fig.s 2 and 4). However, it was 
observed that the films prepared with HPMC-AS, but not the HPMC films, were tacky. The 
tacky nature of the films prepared with HPMC-AS could be attributed to the significantly 
higher moisture content, as observed from thermogravimetric analysis.  
The solid state of pure silodosin and the film formulations were analyzed using PXRD (Fig. 
4). The PXRD pattern of pure silodosin showed sharp, characteristic peaks at 2θ angles of 
approximately 10, 11 and 20, illustrating the crystalline nature of the starting material. This is 
in agreement with the PXRD patterns reported by Singh and Mirmehrabi [38]. These 
characteristic peaks disappeared, and a hollow shape was observed in the PXRD patterns for 
all the HPMC-AS film formulations (F6-F8), which confirms the formation of a solid 
dispersion with the drug uniformly dispersed in the polymer. However, in the case of HPMC 
films (F1-F4), very low intensity diffraction peaks were observed, which suggests that the 
drug may not have been fully dispersed or may have existed as submicron particles in the 
polymer matrix. 
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3.2. Film Morphology 
As shown in Fig. 5, the surface morphology of the pure silodosin and representative film 
formulations were characterized using SEM. The SEM micrographs of the pure silodosin 
show particles with irregular morphology. The HPMC-based films (F2 and F4), but not the 
HPMC-AS-based films (F6 and F8), had submicron silodosin particles and tiny pores (Fig 5). 
This observation was in agreement with the PXRD results. The submicron particles of 
silodosin may have formed at the point of supersaturation in HPMC during preparation of the 
casting gel. Alonzo et al. reported the formation of submicron particles in HPMC-based 
amorphous solid dispersions that were related to the degree of supersaturation [41]. This also 
suggests that more uniform dispersion was obtained in HPMC-AS as a result of the higher 
solubility of silodosin in HPMC-AS than in HPMC [42, 43].  
3.3. Mechanical properties  
The mechanical and tensile properties of the thin films were measured under ambient 
conditions. The EM, TS and EB of the silodosin films are shown in Table 2. TS was greater in 
HPMC-based films than in HPMC-AS-based films, while the EB was longer in HPMC-AS-
based films. Decreasing the content of the polymers reduced the TS of the films. TS and EM 
values decreased by 53% and 54%, respectively, in HPMC samples with a drug:polymer ratio 
of 1:3 compared with a ratio of 1:5. The effect of less polymer was even more profound with 
HPMC-AS; TS and EM decreased by 73% and 86%, respectively. The EB was also affected 
by decreasing the proportion of polymer, increasing in HPMC- and HPMC-AS-based films 
with a drug:polymer ratio of 1:3 by 24% and 67%, respectively, compared with a ratio of 1:5.  
Interestingly, the addition of TPGS had no significant effect on the EM or TS, whereas a 
mixed result was seen for the EB. When TPGS was added to the formulations containing the 
higher proportion of polymer (drug:polymer ratio 1:5), the EB was increased for HMPC films 
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and decreased for HMPC-AS films; however, there was no change in EB when TPGS was 
added to the films containing the lower proportion of polymer (ratio 1:3).  Further studies are 
needed to determine the cause of this difference. 
The ability to sustain TS is important for packaging and handling the thin films. The obtained 
TS values for our HPMC films are similar to those in the literature [20]. Our TS values are 
also comparable to those of the commercial products examined by Pries et al. [44] with 
respect to maximum force, displacement and elongation, particularly in comparison with 
PediaLax and Triaminic® Cold & Cough products. Thus, it can be inferred that our formulated 
batches would be suitable for commercialization. In fact, the elongation properties of the 
HPMC-AS films considerably exceeded those of the commercial products; hence films made 
to this formulation would possess superior toughness. Tensile properties are a function of the 
molecular structure. HPMC-AS has fewer polar substituents, which are known to improve 
elongation, but also to decrease TS [45]. In contrast, while TS was higher with HPMC, the 
films were not as tough, i.e. they were hard and brittle [46].     
3.4. Film thickness, drug content uniformity 
The average thickness of the HPMC-based films (F1-F4) ranged from 106.7±0.0 to 116.7±0.0 
mm while that of the HPMC-AS-based films (F6-F8) ranged from 86.7±0.0 to 106.7±0.0 mm. 
Despite the constant monitoring of processing parameters for all film formulations, there were 
differences in the thicknesses of the two types of film.  These differences were attributed to 
variations in the density of the casting gels for the two polymers as a result of their intrinsic 
polymer properties. Differences in film thickness between films with the same polymer-based 
formulations may have resulted from the different solid contents and drug:polymer ratios 
among the formulations. Evaluation of the drug content in the films showed values ranging 
from 96 ± 28 to 117±28.9 %, as shown in Table 1. These results indicated uniform 
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distribution of drug in the films, within the acceptable limits for standard oral solid dosage 
forms, according to the USP [47, 48].  
3.5. Disintegration time: 
The disintegration times are shown in Table 2. The fastest disintegration was observed with 
the HPMC-AS-based film F5 (drug: polymer ratio 1:5) which disintegrated in 15.3±1.2 sec. 
Disintegration was slower for the film based on the HPMC polymer with the same 
drug:polymer ratio (35.3±0.6 sec). This effect may have been related to the properties of the 
polymer, i.e. wettability and surface tension. Thus, HPMC-AS films disintegrated more 
quickly than HPMC films [49]. Addition of the surfactant (TPGS) to the film formulation had 
an additive effect on the disintegration time (Table 2). These results were in agreement to 
those of Vuddanda et al, who found an additive effect of the surfactant TPGS on speed of 
disintegration, and films containing polymer/surfactant disintegrated faster than HPMC alone 
[23]. Surface tension, wettability, porosity and intra- and inter-molecular interactions between 
polymer composed materials can affect both disintegration and dissolution [49]. TPGS based 
films showed a better disintegration because of reduced surface tension and enhanced 
wettability.  
3.6. In vitro dissolution in simulated saliva 
The solubility of pure silodosin in simulated saliva was 0.46 mg/mL. The solubility of 
silodosin in simulated saliva with additional dissolved HPMC (with and without TPGS) 
ranged from 0.48 to 0.51 mg/mL at equilibrium after 48 hours, and with additional dissolved 
HPMC-AS (with and without TPGS) ranged from 0.94 to 1.1 mg/mL. The dissolution results 
for the films formulated using HPMC and HPMC-AS are shown in Fig.s 6a and 6b, 
respectively. In the HPMC-based films, 80% of the drug was released in 10 minutes from F2 
(with a drug:polymer ratio of 1:3), while dissolution was poorer for F1 (1:5 drug:polymer 
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ratio), with 80% release after 25 minutes. This may be because the increase in polymer 
concentration led to the formation of a gel-like state which decreased water uptake and 
retarded drug release, as reported by Singh and Harmanpreet [50]. Alhayali et al. have 
previously reported that, in some cases of solid drug dispersions, the drug concentrations do 
not change with different drug:polymer ratios [51].  Addition of TPGS also improved the drug 
release noticeably. Thus, films containing TPGS dissolved faster than TPGS-free films. Other 
workers have mentioned this effect of the surfactant TPGS in terms of its ability to improve 
the solubility, dissolution rate and bioavailability of some drugs formulated as oral films [52, 
23].  
In HPMC-AS-based films, about 80% of the drug was released in around 10 minutes (F5 and 
F6), with no significant differences in dissolution rate between the two ratios (1:3 and 1:5). 
Addition of the surfactant TPGS to the HPMC-AS-based films negatively affected the 
dissolution rate for both ratios. Therefore, this study has demonstrated that HPMC works well 
as a film-forming polymer when combined with TPGS. In a case study by Garsuch and 
Verena [19], HPMC was the most suitable film-forming material of the excipients tested, 
providing faster dissolution and easier-to-handle films. Interestingly, the submicron particles 
appear not to have affected the faster drug release from HPMC films. Further, it was observed 
that the dissolution behavior of HPMC-AS (TPGS-free) films was similar to that of HPMC 
films containing amorphous solid dispersions (Fig. 6).  
The dissolution studies were conducted in simulated saliva (pH 6.8) under non-sink 
conditions, mimicking the conditions of the oral cavity. These studies suggested that both 
polymers are capable of increasing and prolonging the supersaturation of the drug and helping 
to prevent the tendency of the drug to precipitate and recrystallize during dissolution. This 
could be attributed to the existence of the drug in the amorphous state and molecularly 
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dispersed in the polymer matrix. This was also evident from the thermal, solid-state and 
morphological results.  
It has been reported that cellulose-derived polymers such as HPMC, HPMC-AS and 
hypromellose phthalate (HPMCP) are superior for preparing solid, amorphous dispersions, 
particularly with poorly water-soluble drugs, compared to other polymers. The bulky structure 
of the polymer network and worse solubility properties (compared to highly water-soluble 
polymers) facilitate the reduction of drug mobility in the polymer matrix and prevent the drug 
from recrystallizing as normally induced by supersaturation during dissolution [53]. This 
consequently improves the product’s physical stability and in vitro drug release performance. 
In general, our dissolution results revealed that HPMC and HPMC-AS would be useful for 
preparing films intended for oral cavity absorption, which is more complex than GIT 
absorption.  
The DS values for silodosin formulated as an oral film are presented in Fig. 7. The highest DS 
was obtained for HPMC-based formulations at early time points. F4, in particular, had a DS 
value of > 1 (supersaturated) before 5 minutes, which was earlier than the other films 
formulated using the HPMC polymer (F1-F3), as shown in Fig. 7. In the dissolution results, 
80% of the drug was released from film formulation F4 during the first 10 minutes (Fig. 6). 
This effect could be attributed to the synergistic effect of the surfactant (TPGS) and the 
polymer (HPMC), resulting in improved solubility and maintained supersaturation [54, 55, 
56]. Therefore, film formulation F4 appears to have potential for the development of a 
silodosin film formulation with improved performance and improved oral sublingual 
absorption as a result of the high degree of supersaturation solubility [57, 58]. 
4. Conclusions 
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Oral films of silodosin intended for the sublingual administration route were prepared 
successfully for the first time. DSC studies confirmed the existence of silodosin in an 
amorphous form in films formulated with HPMC or HPMC-AS. SEM and PXRD studies 
revealed the presence of submicron particles of the drug in HPMC-based films, while the drug 
remained fully amorphous in HPMC-AS films. The mechanical properties of HPMC films 
were better than those of HPMC-AS films with respect to stability during patient handling and 
packing. The dissolution behavior of HPMC was similar to that of HPMC-AS when the 
surfactant TPGS was added (0.5 % w/w) to the HPMC film formulation. TPGS at the tested 
concentration had no effect on the dissolution of the drug in HPMC-AS-based formulations. 
Silodosin formulation F4 had a DS >1, which could be promising for improving its oral 
absorption. Further studies are required to evaluate the dissolution of the film in human saliva, 
and to investigate the permeability of the oral cavity to the drug and the drug absorption 
characteristics. Film palatability and crystallization during storage (stability) also require 
investigation.  
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Table1. Silodosin oral films. Summary of the drug:polymer ratios for the eight developed 
films, and the mean thickness, speed of disintegration and drug content ± SD (n ≥ 3).  
Formulation 
code 
Drug:polymer 
ratio 
Thickness** 
(mm) 
Disintegration time 
(seconds) 
Drug 
content 
(mg) 
F1 1:5 (Silodosin:HPMC) 106.7±0.0 35.3±0.6 96±28 
F2 1:3 (Silodosin:HPMC) 110±0.0 61.0±0.0 97 ±5.8 
F3* 1:5 (Silodosin:HPMC) 116.7±0.0 65.7±0.6 96±1.1 
F4* 1:3 (Silodosin:HPMC) 113±0.0 62.7±1.5 104 ±26.1 
F5 1:5 (Silodosin:HPMC-AS) 106.7±0.0 15.3±1.2 98 ±6.5 
F6 1:3 (Silodosin:HPMC-AS) 86.7±0.0 33.7±2.5 113±18.4 
F7* 1:5 (Silodosin:HPMC-AS) 90±0.0 33.0±1.0 117±28.9 
F8* 1:3 (Silodosin:HPMC-AS) 86.7±0.0 56.7±0.6 99±19.8 
HPMC = hydroxypropyl methylcellulose; HPMC-AS = hydroxypropyl methylcellulose 
acetate succinate. 
*Four films (F3, F4, F7 and F8) also contained the surfactant tocopherol polyethylene glycol 
succinate. 
**Standard deviation values for all investigated formulations are too small. 
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Table 2: Mechanical properties of silodosin films 
Means ± SD (n ≥ 5) 
Film 
(F) 
Young´s Modulus 
(Mpa) 
Max. Tensile 
Strength 
(Mpa) 
Elongation at Break 
(%) 
1 490±63 10.08±1.59 3.82±0.96 
2 225±120 4.74±2.66 4.74±2.21 
3 458±34 9.81±0.67 6.35±0.45 
4 158±17 3.29±0.25 4.44±0.71 
5 337±25 7.31±3.01 12.31±1.33 
6 48±19 1.94±0.29 20.57±3.95 
7 314±25 6.91±0.96 8.53±1.16 
8 54±11 1.99±0.17 20.98±4.33 
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Figure captions 
Figure 1 
Differential scanning calorimetry results for drug-polymer miscibility determination. 
Figure 2 
Differential scanning calorimetry results for the silodosin film formulations. HPMC-based 
films, F1-F4; and HPMC-AS-based films, F5-F8. 
Figure 3 
Thermogravimetric analysis results for the formulated silodosin films showing moisture 
content.  
Figure 4 
X-ray diffraction patterns for pure crystalline silodosin and the developed films (F1-F8). 
Figure 5 
Scanning electron microscopy micrographs for the formulated films and the pure drug 
(silodosin).  The bar represents 100 µm for F2, F4, F6, and F8, and 20 µm for pure silodosin.  
Figure 6 
Film dissolution in simulated saliva for (a) the HPMC-based films and (b) the HPMC-AS-
based films. n=3 ± SD 
Figure 7 
Degree of supersaturation as a result of formulating the drug silodosin in film formulations 
containing HPMC (F1-F4) or HPMC-AS (F5-F8). n= 3± SD 
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